Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2016

01-04-2016 | Erratum

Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

Authors: Seth A. Wander, Dekuang Zhao, Alexandra H. Besser, Feng Hong, Jianqin Wei, Tan A. Ince, Clara Milikowski, Nanette H. Bishopric, Andy J. Minn, Chad J. Creighton, Joyce M. Slingerland

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Login to get access

Excerpt

In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum.
Metadata
Title
Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy
Authors
Seth A. Wander
Dekuang Zhao
Alexandra H. Besser
Feng Hong
Jianqin Wei
Tan A. Ince
Clara Milikowski
Nanette H. Bishopric
Andy J. Minn
Chad J. Creighton
Joyce M. Slingerland
Publication date
01-04-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3752-9

Other articles of this Issue 2/2016

Breast Cancer Research and Treatment 2/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine